Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed medicines -- the only ones in the world -- that target the underlying causes of a rare disease called cystic fibrosis (CF).
So far, Vertex's monopoly has remained intact despite many of its peers trying to break into this space. But could that change soon? Sionna Therapeutics, a privately held biotech, certainly hopes so.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
453,20 €
-3,26 %
Hohe Buy- und niedrige Sell-Zahlen bei Vertex Pharmaceuticals Inc. zeigen ein stark positives Sentiment.
Ein unerwartetes negatives Potenzial von -0.71% für Vertex Pharmaceuticals Inc., trotz eines niedrigeren Kursziels von 450 € als der aktuelle Kurs von 453.2 €.
